Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed.

Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed.

The present invention relates to compositions for use and formulation as weight management products and in particular fermented dairy foodstuffs. The compositions generally comprise two or more of the following components: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying 5 component and at least one of the following: d) Streptococcus thermophilus CBS 139100 and Lactobacillus delbrueckii subsp. bulgaricus CBS 139099 microbial strains or mutant strains or fragments or fractions thereof; e) a combination of Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus microbial strains which together, or individually, are capable of secreting polysaccharides having high levels of galactosamine 10 and no or low levels of rhamnose and glucuronic acid when grown on a dairy substrate; or f) polysaccharides formed of: i) 15-25% galactosamine; ii) 45-60% galactose; and iii) 20-30% glucose. The compositions may also be useful in the management or treatment of obesity, elevated cholesterol, diabetes, hypertension or heart disease.

The present invention relates to compositions for use and formulation as weight management products and in particular fermented dairy foodstuffs. The compositions generally comprise two or more of the following components: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying 5 component and at least one of the following: d) Streptococcus thermophilus CBS 139100 and Lactobacillus delbrueckii subsp. bulgaricus CBS 139099 microbial strains or mutant strains or fragments or fractions thereof; e) a combination of Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus microbial strains which together, or individually, are capable of secreting polysaccharides having high levels of galactosamine 10 and no or low levels of rhamnose and glucuronic acid when grown on a dairy substrate; or f) polysaccharides formed of: i) 15-25% galactosamine; ii) 45-60% galactose; and iii) 20-30% glucose. The compositions may also be useful in the management or treatment of obesity, elevated cholesterol, diabetes, hypertension or heart disease.

A method for treating a cerebrovascular disease according to an embodiment of the present disclosure includes administering a composition comprising at least one of melittin and magnetic iron oxide nanoparticle loaded with melittin as an effective component to a subject in need thereof. A composition according to an embodiment of the present disclosure for preventing, ameliorating, or treating a cerebrovascular disease includes melittin or magnetic iron oxide nanoparticle loaded with melittin as an effective component. The melittin or magnetic iron oxide nanoparticle loaded with melittin not only can reduce the diameter of cerebral arteries, increase the thickness of cerebral arteries, increase the content of elastin and smooth muscles, and reduce the content of abnormal collagen but also has an effect of suppressing the expression of the factors which mediate an inflammatory response.

A method for treating a cerebrovascular disease according to an embodiment of the present disclosure includes administering a composition comprising at least one of melittin and magnetic iron oxide nanoparticle loaded with melittin as an effective component to a subject in need thereof. A composition according to an embodiment of the present disclosure for preventing, ameliorating, or treating a cerebrovascular disease includes melittin or magnetic iron oxide nanoparticle loaded with melittin as an effective component. The melittin or magnetic iron oxide nanoparticle loaded with melittin not only can reduce the diameter of cerebral arteries, increase the thickness of cerebral arteries, increase the content of elastin and smooth muscles, and reduce the content of abnormal collagen but also has an effect of suppressing the expression of the factors which mediate an inflammatory response.

The present invention provides a cholesterol reducing probiotic strain, composition thereof and use thereof. The probiotic strain is Lactobacillus plantarum TCI507, which itself and its metabolites can effectively reduce the cholesterol content, enhance the gene expression level of SCARB1, APOA1, and LDLR to promote the effect of cholesterol metabolism, and can effectively reduce the total cholesterol and the low-density lipoprotein in human blood.

The present invention provides a cholesterol reducing probiotic strain, composition thereof and use thereof. The probiotic strain is Lactobacillus plantarum TCI507, which itself and its metabolites can effectively reduce the cholesterol content, enhance the gene expression level of SCARB1, APOA1, and LDLR to promote the effect of cholesterol metabolism, and can effectively reduce the total cholesterol and the low-density lipoprotein in human blood.

The invention relates to preparation comprising at least one probiotic strain belonging to the genus Bacillus megaterium, and a polyunsaturated fatty acid component comprising at least one omega-3 or omega-6 fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (ARA), alpha linolenic acid, stearidonic acid, eicosatetraenoic acid, docosapentaenoic acid, linoleic acid, γ-linolenic acid, wherein the polyunsaturated fatty acid component comprises an omega-3 or omega-6 fatty acid salt. The invention further relates to use of the inventive preparation as a feed or food supplement, pharmaceutical product, feed-or foodstuff compositions and for topical applications.

The invention relates to preparation comprising at least one probiotic strain belonging to the genus Bacillus megaterium, and a polyunsaturated fatty acid component comprising at least one omega-3 or omega-6 fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (ARA), alpha linolenic acid, stearidonic acid, eicosatetraenoic acid, docosapentaenoic acid, linoleic acid, γ-linolenic acid, wherein the polyunsaturated fatty acid component comprises an omega-3 or omega-6 fatty acid salt. The invention further relates to use of the inventive preparation as a feed or food supplement, pharmaceutical product, feed-or foodstuff compositions and for topical applications.